In a clinical trial, TRELSTAR lowered and maintained testosterone below castration levels†1
- Primary Endpoint Results: Castration levels of serum testosterone (≤ 1.735 nmol/L; equivalent to 50 ng/dL) in patients treated with TRELSTAR 3.75 mg were achieved at Day 29 in 125 of 137 (91.2%) patients and at Day 57 in 97.7% of patients. Maintenance of castration levels of serum testosterone from Day 57 through Day 253 was found in 96.2% of patients treated with TRELSTAR 3.75 mg.
Fewer testosterone breakthroughs than Lupron® in a head‑to‑head study†2,3
- 4 TRELSTAR escapes occurred within the first 2 months of therapy only
- 11 leuprolide acetate escapes occurred throughout the entire 9‑month study period
- TRELSTAR mean T Level over 9 months was 8 ng/dL
Testosterone and PSA suppression regardless of strength†§¶2
- > 96% reduction in PSA level from baseline to end of study
DOSING SCHEDULES YOU CAN COUNT ON TO HELP MAINTAIN LOW T
TRELSTAR is available in 3 convenient dosage strengths with distinct dosing schedules to meet the individual needs of your patients.‡1
Study Designs
†3.75 mg: Based on a 9-month, multicenter, parallel-group, double-blind, randomized, controlled clinical trial comparing TRELSTAR 3.75 mg to leuprolide acetate (7.5 mg) in patients with advanced (stage C/D) prostate cancer (N = 284). Mean testosterone levels were calculated for Months 2 to 9. The primary efficacy endpoints were both achievement of castration by Day 29 and maintenance of castration from Day 57 through Day 253.1,3
§11.25 mg: In a study of similar design, patients received either TRELSTAR 11.25 mg (N = 174) every 12 weeks for a total of up to 3 doses (maximum treatment period of 253 days) or TRELSTAR 3.75 mg (N = 172) every 28 days for a total of up to 9 doses. The primary efficacy endpoints were both achievement of castration by Day 29 and maintenance of castration from Day 57 through Day 253.1
¶22.5 mg: In a non-comparative trial, patients received TRELSTAR 22.5 mg (N = 120) every 24 weeks for a total of 2 doses (maximum treatment period of 337 days). The primary efficacy endpoints included achievement of castration by Day 29 and maintenance of castration from Day 57 through Day 337.1